Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2025 Earnings Presentation
14 slides from Nexstim's earnings presentation, Aug 15, 2025
Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim - Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H1 2025 Financial Results Webinar, 15 August 2025
Slide 2: Nexstim Oyj
System and service sales volume increase through a successful Brainlab Continued development of competitive partnership bridging neuro- system and service offering in approved surgery, neurophysiology indications (Depression & Chronic Pain). and neuroscience. Expansion into possible new indications
Slide 3: Nexstim Plc Public Presentation
Nexstim Plc Public Presentation 3
Slide 4: Nexstim and Brainlab collaboration on development and distributorship
Nexstim and Brainlab have started a collaboration by signing a development and distributorship cooperation agreement. Nexstim has created a world-leading non- invasive brain mapping technology based on navigated transcranial magnetic stimulation. Together, the two companies will develop new solution
Slide 5: Non-invasive brain motor mapping in 20 minutes
Non-invasive brain motor mapping in 20 minutes 1 Prepare Upload the 2 Register Register the 3 Stimulate 3D mapping of 4 Evaluate Review areas eliciting 5 Export Bring data into MRI image patient head to the brain responses to avoid surgical planning their MRI during surgery and navigation tools Nexs
Slide 6: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS 5 Diagnostics (Navigated Over 250 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® & NBS 6 Over 110 Depression CE marked with existing Therapy (Navig
Slide 7: Business and Financial Summary H1 2025
Nexstim Business and Financial Summary H1 2025 • Nexstim accelerated growth and improved profitability • System sales were EUR 2.2M (2024 H1: EUR 1.2M), with an • In line with our main strategic objective, we have focused on increase of 79.7%. Recurring net sales were EUR 2.1M (2024 profitable reven
Slide 8: Financial Development H1 2023-2025 (k€)
Nexstim Financial Development H1 2023-2025 (k€) 5 000,0 +42 % 4 000,0 +27 % 3 000,0 2 000,0 1 000,0 GM%: GM%: GM%: 80 82 81 0,0 H1 23 H1 24 H1 25 -1 000,0 -2 000,0 Net sales Gross margin EBITDA Nexstim Oyj Nexstim Plc Public Presentation 8
Slide 9: Group Key Financials H1
Nexstim Group Key Financials H1 • Net Sales 4.5M€ +42 % 1–6/2025 1–6/2024 1–12/2024 EUR in thousands 6 months 6 months Change-% 12 months • System sales 2.2M€ +80 % • Recurring 2.1M€ +8 % • Licensing 0.2M€ Net Sales 4,506 3,177 41.8 % 8,735 • Diagnostic 2.5M€ +65 % Comparable net sales 4,306 3,177 3
Slide 10: Trailing 12mths Net Sales, Gross Margin and EBITDA
Trailing 12mths Net Sales, Gross Margin and EBITDA 2023- 2025 12 000,0 Growth: +92 % 10 000,0 CAGR: +39 % over 2 years 8 000,0 6 000,0 4 000,0 2 000,0 0,0 H2 22 + H1 23 FY 23 H2 23 + H1 24 FY 24 H2 24 + H1 25 -2 000,0 -4 000,0 Net sales Gorss margin EBITDA Nexstim Oyj Nexstim Plc Public Presentation
Slide 11: Key Strategic Objectives 2025
Nexstim Key Strategic Objectives 2025 1 2 3 Profitable Growth Strategic Partnerships Technology leadership Increase net sales and Successfully supporting Launching the new NBS 6 improve operating result the long-term diagnostics system in key for the financial year collaboration between markets, ena
Slide 12: NBS 6 – future of the Nexstim system
NBS 6 – future of the Nexstim system Commercialization of the new product generation is an essential part of Nexstim’s 2025-2028 strategy period • The NBS 6 is a new combined system that has been built on Nexstim’s unique, clinically established technology. • The modular product design allows for an
Slide 13: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim Nexstim Oyj Nexstim Plc Public Presentation 13
Slide 14: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj as, a promise or representation as to future performance. The Company does not undertake any (“Nexstim” or the “Company”). In connection with any presentation or review of this document, oblig